Compare · BDX vs LUNG
BDX vs LUNG
Side-by-side comparison of Becton Dickinson and Company (BDX) and Pulmonx Corporation (LUNG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and LUNG operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.58B, about 737.0x LUNG ($59.1M).
- Over the past year, BDX is down 11.6% and LUNG is down 56.0% - BDX leads by 44.4 points.
- BDX has been more active in the news (8 items in the past 4 weeks vs 1 for LUNG).
- BDX has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- Becton Dickinson and Company
- Pulmonx Corporation
- Price
- $158.16-1.07%
- $1.39-4.14%
- Market cap
- $43.58B
- $59.1M
- 1M return
- +8.93%
- +11.65%
- 1Y return
- -11.60%
- -56.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 1
- Recent ratings
- 25
- 17
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest LUNG
- Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
- Director Burns Thomas William was granted 40,000 shares, increasing direct ownership by 54% to 113,399 units (SEC Form 4)
- Director Ferrari Richard was granted 40,000 shares, increasing direct ownership by 46% to 127,024 units (SEC Form 4)
- Director Florin Daniel P was granted 40,000 shares, increasing direct ownership by 43% to 133,910 units (SEC Form 4)
- Director Melenikiotou Georgia was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
- Director Sullivan Tiffany was granted 40,000 shares, increasing direct ownership by 53% to 115,199 units (SEC Form 4)
- Director Mead Dana G Jr. was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
- Pulmonx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Science &Techn. Officer Radhakrishnan Srikanth sold $22,325 worth of shares (14,497 units at $1.54), decreasing direct ownership by 4% to 331,239 units (SEC Form 4) to cover withholding tax
- GENERAL COUNSEL Lehman David Aaron sold $22,475 worth of shares (14,594 units at $1.54), decreasing direct ownership by 4% to 376,161 units (SEC Form 4) (withholding obligation)